Photo of James W. Mier,  MD

James W. Mier, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-0430
Fax: (617) 975-5398


jmier@caregroup.Harvard.edu

James W. Mier, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

Our laboratory is interested in the signaling pathways downstream of ras that are involved in the regulation of expression of actin-binding proteins such as tropomyosin (TM) that have been shown to affect the growth and metastatic potential of tumor cells. We have shown that the expression of TM-2 is suppressed by oncogenic ras through a pathway that involves Raf, but not MEK. To further clarify the specific pathway involved, we are assessing the effects of various dominant negative fibroblasts and epithelial cells. Our laboratory is also interested in the factors that regulate the expression of the leukocyte adhesion molecule L-selection. Unlike most adhesion molecules, L-selectin is shed from the cell surface in response to leukocyte activation or exposure to L-selectin ligands. Ligand-induced shedding appears to be mediated by a protease distinct from the recently characterized ADAMS family member TACE (TNF-Alpha Converting Enzyme), which is responsible for the shedding of L-selectin in response to leukocyte activation. We are currently investigating the signaling pathways activated by encountering L-selectin ligands.

Publications

Powered by Harvard Catalyst
  • Mier JW. Immune Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. Clin Ther 2015. PubMed
  • McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21:561-8. PubMed
  • Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res 2015. PubMed
  • Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS. The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma. Transl Oncol 2014. PubMed
  • Panka DJ, Mier JW, Sullivan RJ. Assaying for BRAF V600E in tissue and blood in melanoma. Methods Mol Biol 2013; 1102:117-36. PubMed
  • Zhu S, Cohen MB, Bjorge JD, Mier JW, Cho DC. PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells. J Cell Mol Med 2013; 17:377-85. PubMed
  • Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer 2013; 108:319-26. PubMed
  • Cho DC, Mier JW. Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma. Curr Cancer Drug Targets 2013; 13:126-42. PubMed
  • Panka DJ, Liu Q, Geissler AK, Mier JW. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol Cancer 2013; 12:17. PubMed
  • Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase i first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 2012; 18:3396-406. PubMed
  • Pandya SS, Mier JW, McDermott DF, Cho DC. Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. BJU Int 2011. PubMed
  • Panka DJ, Sullivan RJ, Mier JW. An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res 2010; 20:401-7. PubMed
  • Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010; 9:2793-802. PubMed
  • Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clin Cancer Res 2010; 16:3628-38. PubMed
  • Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer 2009; 115:2247-51. PubMed
  • Cho DC,Puzanov I,Regan MM,Schwarzberg T,Seery V,Lee MY,Liu V,Bhatt R,Koon H,Mier JW,Sosman JA,Atkins MB,McDermott DF. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009; 32:181-5. PubMed
  • Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 2008; 26:2292-8. PubMed
  • Negin B, Panka D, Wang W, Siddiqui M, Tawa N, Mullen J, Tahan S, Mandato L, Polivy A, Mier J, Atkins M. Effect of melanoma on immune function in the regional lymph node basin. Clin Cancer Res 2008; 14:654-9. PubMed
  • Panka DJ, Cho DC, Atkins MB, Mier JW. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem 2007; 283:726-32. PubMed
  • Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007; 13:758s-763s. PubMed
  • Cho D, Atkins MB, Mier JW. Inhibition of glycogen synthase 3b (GSK3b) enhances the in vitro activity of the Akt inhibitor perifosine in renal cell carcinoma (RCC) cell lines J Am Diet Assoc 2006.
  • Cho D, Panka P, Panka D, Atkins MB, Mier JW. Sensitivity of renal cell carcinoma (RCC) cell lines to Sorafenib in vitro is dependent upon Akt and GSK3activity J Am Diet Assoc 2006; 2006:4515.
  • Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, Jewell RC, Bell WN, Thurmond LM, Weisenbach J, Roberts S, Dar MM. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006; 12:4265-73. PubMed
  • Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 2006; 12:2291s-2296s. PubMed
  • Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res 2006; 12:2371s-2375s. PubMed
  • Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006; 66:1611-9. PubMed
  • Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11:3714-21. PubMed
  • Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8. PubMed
  • McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 23:133-41. PubMed
  • Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10:4699-708. PubMed
  • Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003; 278:37632-6. PubMed
  • Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003; 21:2564-73. PubMed
  • Mier JW. Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF. J Immunother 2003; 26:95-6. PubMed
  • Janssen RA, Kim PN, Mier JW, Morrison DK. Overexpression of kinase suppressor of Ras upregulates the high-molecular-weight tropomyosin isoforms in ras-transformed NIH 3T3 fibroblasts. Mol Cell Biol 2003; 23:1786-97. PubMed
  • Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2002; 8:3075-81. PubMed
  • Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 2001; 19:3194-202. PubMed
  • Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 2001; 276:6893-6. PubMed
  • Atkins MB, Redman B, Mier J, Gollob J, Weber J, Sosman J, MacPherson BL, Plasse T. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin Cancer Res 2001; 7:486-92. PubMed
  • Atkins MB, Dutcher J, Weiss G, Margolin K, Clark J, Sosman J, Logan T, Aronson F, Mier J,. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials. Med Oncol 2002; 18:197-207. PubMed
  • Gollob JA, Mier JW, Atkins MB. Clinical use of systemic IL-12 therapy. Cancer Chemother Biol Response Modif 2001; 19:353-69. PubMed
  • Dutcher J, Atkins MB, Margolin K, Weiss G, Clark J, Sosman J, Logan T, Aronson F, Mier J,. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2002; 18:209-19. PubMed
  • Gollob JA, Veenstra KG, Mier JW, Atkins MB. Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother 2001; 24:91-8. PubMed
  • Gollob JA, Veenstra KG, Jyonouchi H, Kelly AM, Ferrieri P, Panka DJ, Altare F, Fieschi C, Casanova JL, Frank DA, Mier JW. Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections. J Immunol 2000; 165:4120-6. PubMed
  • Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000; 6:3442-50. PubMed
  • McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000; 6:2201-8. PubMed
  • Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6:1678-92. PubMed
  • Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275:1209-15. PubMed
  • Bhatt R, Wang X, Zhang L, Bhasin M, Libermann T, O’Neil A, Signoretti S, Atkins M, Mier J, Goldberg SN. Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models. 2009.
  • Panka DJ, Collins M, Atkins MB, Signoretti S, Mier JW. Enhancement of efficacy of sorafenib and sunitinib with the HDM2 antagonist MI-319 in RCC tumor xenografts. 2010.
  • Bhatt RS, Zhang L, Bullock A, Moreno K, Signoretti S, Atkins M, Sabbadini R, Mier J. Sphingosine-1-phosphate (S1P) as a novel target in renal cancer (RCC). 2010.
  • Bullock AJ, Zhang L, AM O’Neill, Percy A, Sukhatme V, Mier JW, Atkins MB, Bhatt RS. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC) 2010.
  • Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw 1999; 10:37-42. PubMed
  • Janssen RA, Veenstra KG, Jonasch P, Jonasch E, Mier JW. Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent. J Biol Chem 1998; 273:32182-6. PubMed
  • Potter DA, Tirnauer JS, Janssen R, Croall DE, Hughes CN, Fiacco KA, Mier JW, Maki M, Herman IM. Calpain regulates actin remodeling during cell spreading. J Cell Biol 1998; 141:647-62. PubMed
  • McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin Cancer Res 1998; 4:1203-13. PubMed
  • Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18:428-32. PubMed
  • Janssen RA, Mier JW. Tropomyosin-2 cDNA lacking the 3' untranslated region riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts. Mol Biol Cell 1997; 8:897-908. PubMed
  • Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1998; 3:409-17. PubMed
  • Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997; 15:1052-62. PubMed
  • Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin Cancer Res 1998; 3:39-46. PubMed
  • Stoddart JH, Jasuja RR, Sikorski MA, von Andrian UH, Mier JW. Protease-resistant L-selectin mutants. Down-modulation by cross-linking but not cellular activation. J Immunol 1996; 157:5653-9. PubMed
  • Sikorski MA, Staunton DE, Mier JW. L-selectin crosslinking induces integrin-dependent adhesion: evidence for a signaling pathway involving PTK but not PKC. Cell Adhes Commun 1996; 4:355-67. PubMed
  • Trehu EG, Mier JW, Dubois JS, Sorce D, Klempner MS, Epstein M, Dinarello CA, Shapiro L, Kappler K, Ronayne L, Atkins MB. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res 1998; 2:1341-51. PubMed
  • Ryan CM, Atkins MB, Mier JW, Gelfand JA, Tompkins RG. Effects of malignancy and interleukin-2 infusion on gut macromolecular permeability. Crit Care Med 1995; 23:1801-6. PubMed
  • Tilg H, Atkins MB, Dinarello CA, Mier JW. Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy. Cytokine 1995; 7:734-9. PubMed
  • Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkman EM. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood 1995; 86:1288-91. PubMed
  • Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, Dinarello CA, Mier JW. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. J Immunol 1994; 152:3189-98. PubMed
  • Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83:113-8. PubMed
  • Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med 1993; 178:1629-36. PubMed
  • Tilg H, Shapiro L, Atkins MB, Dinarello CA, Mier JW. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol 1993; 151:3299-307. PubMed
  • Tilg H, Mier JW, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993; 150:4687-92. PubMed
  • Numerof RP, Sipe JD, Trehu EG, Dinarello CA, Mier JW. Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist. Cytokine 1992; 4:555-60. PubMed
  • Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Mier JW. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 1991; 78:2505-13. PubMed
  • Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Brandon EP, Laird W, Atkins MB. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990; 76:1933-40. PubMed
  • Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990; 322:959-65. PubMed
  • Mier JW, Brandon EP, Libby P, Janicka MW, Aronson FR. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. J Immunol 1989; 143:2407-14. PubMed
  • Numerof RP, Aronson FR, Mier JW. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol 1988; 141:4250-7. PubMed
  • Aronson FR, Libby P, Brandon EP, Janicka MW, Mier JW. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol 1988; 141:158-63. PubMed
  • Mier JW, Dinarello CA, Atkins MB, Punsal PI, Perlmutter DH. Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells. J Immunol 1987; 139:1268-72. PubMed
  • Dempsey RA, Dinarello CA, Mier JW, Rosenwasser LJ, Allegretta M, Brown TE, Parkinson DR. The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol 1982; 129:2504-10. PubMed
  • Krensky AM, Reiss CS, Mier JW, Strominger JL, Burakoff SJ. Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc Natl Acad Sci U S A 1982; 79:2365-9. PubMed
  • Mier JW, Gallo RC. The purification and properties of human T cell growth factor. J Immunol 1982; 128:1122-7. PubMed
  • Gootenberg JE, Ruscetti FW, Mier JW, Gazdar A, Gallo RC. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 1981; 154:1403-18. PubMed
  • Poiesz BJ, Ruscetti FW, Mier JW, Woods AM, Gallo RC. T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci U S A 1980; 77:6815-9. PubMed
  • Mier JW, Gallo RC. Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A 1980; 77:6134-8. PubMed
  • Reiss CS, Hemler ME, Englehard VH, Mier JW, Strominger JL, Burakoff SJ. Development and characterization of allospecific long-term human cytolytic T-cell lines. Proc Natl Acad Sci U S A 1980; 77:5432-6. PubMed
  • Ruscetti FW, Mier JW, Gallo RC. Human T-cell growth factor: parameters for production. J Supramol Struct 1979; 13:229-41. PubMed
Hide